68 related articles for article (PubMed ID: 24403466)
21. [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy.
Berriolo-Riedinger A; Touzery C; Riedinger JM; Toubeau M; Coudert B; Arnould L; Boichot C; Cochet A; Fumoleau P; Brunotte F
Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1915-24. PubMed ID: 17579854
[TBL] [Abstract][Full Text] [Related]
22. Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel (1)H-magnetic resonance spectroscopy and (18)F-fluorodeoxyglucose positron emission tomography.
Cho N; Im SA; Kang KW; Park IA; Song IC; Lee KH; Kim TY; Lee H; Chun IK; Yoon HJ; Moon WK
Eur Radiol; 2016 Jul; 26(7):2279-90. PubMed ID: 26376886
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the Response to Breast Cancer Neoadjuvant Chemotherapy Using 18F-FDG Positron Emission Mammography Compared With Whole-Body 18F-FDG PET: A Prospective Observational Study.
Noritake M; Narui K; Kaneta T; Sugae S; Sakamaki K; Inoue T; Ishikawa T
Clin Nucl Med; 2017 Mar; 42(3):169-175. PubMed ID: 28072617
[TBL] [Abstract][Full Text] [Related]
24. The role of chemotherapeutic drugs in the evaluation of breast tumour response to chemotherapy using serial FDG-PET.
Schneider-Kolsky ME; Hart S; Fox J; Midolo P; Stuckey J; Hofman M; Ganju V
Breast Cancer Res; 2010; 12(3):R37. PubMed ID: 20565953
[TBL] [Abstract][Full Text] [Related]
25. 18F-FDG PET SUVmax correlates with osteosarcoma histologic response to neoadjuvant chemotherapy: preclinical evaluation in an orthotopic rat model.
Dutour A; Decouvelaere AV; Monteil J; Duclos ME; Roualdes O; Rousseau R; Marec-Bérard P
J Nucl Med; 2009 Sep; 50(9):1533-40. PubMed ID: 19690032
[TBL] [Abstract][Full Text] [Related]
26. ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography for Evaluating the Response to Neoadjuvant Chemotherapy in Advanced Esophageal Cancer.
Tani Y; Nakajima M; Kikuchi M; Ihara K; Muroi H; Takahashi M; Domeki Y; Okamoto K; Yamaguchi S; Sasaki K; Tsuchioka T; Sakamoto S; Kato H
Anticancer Res; 2016 Jan; 36(1):367-73. PubMed ID: 26722067
[TBL] [Abstract][Full Text] [Related]
27. [18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy.
Martoni AA; Fanti S; Zamagni C; Rosati M; De Iaco P; D'Errico Grigioni A; Castellucci P; Quercia S; Musto A; Ricci Maccarini L; Lopci E; Bernardi A
Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):81-90. PubMed ID: 21068714
[TBL] [Abstract][Full Text] [Related]
28. 18F-fluorodeoxyglucose positron emission tomography optimizes neoadjuvant chemotherapy for primary breast cancer to achieve pathological complete response.
Ueda S; Saeki T; Shigekawa T; Omata J; Moriya T; Yamamoto J; Osaki A; Fujiuchi N; Misumi M; Takeuchi H; Sakurai T; Tsuda H; Tamura K; Ishida J; Abe Y; Imabayashi E; Kuji I; Matsuda H
Int J Clin Oncol; 2012 Jun; 17(3):276-82. PubMed ID: 21830087
[TBL] [Abstract][Full Text] [Related]
29. Predictive value of [18F]FDG PET for pathological response of breast cancer to neo-adjuvant chemotherapy.
Kim SJ; Kim SK; Lee ES; Ro J; Kang Sh
Ann Oncol; 2004 Sep; 15(9):1352-7. PubMed ID: 15319241
[TBL] [Abstract][Full Text] [Related]
30. Can positron emission tomography/computed tomography with the dual tracers fluorine-18 fluoroestradiol and fluorodeoxyglucose predict neoadjuvant chemotherapy response of breast cancer?--A pilot study.
Yang Z; Sun Y; Xue J; Yao Z; Xu J; Cheng J; Shi W; Zhu B; Zhang Y; Zhang Y
PLoS One; 2013; 8(10):e78192. PubMed ID: 24205151
[TBL] [Abstract][Full Text] [Related]
31. Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy.
Keam B; Im SA; Koh Y; Han SW; Oh DY; Cho N; Kim JH; Han W; Kang KW; Moon WK; Kim TY; Park IA; Noh DY; Chung JK; Bang YJ
BMC Cancer; 2011 Oct; 11():452. PubMed ID: 22011459
[TBL] [Abstract][Full Text] [Related]
32. Monitoring of early response to neoadjuvant chemotherapy in stage II and III breast cancer by [18F]fluorodeoxyglucose positron emission tomography.
Rousseau C; Devillers A; Sagan C; Ferrer L; Bridji B; Campion L; Ricaud M; Bourbouloux E; Doutriaux I; Clouet M; Berton-Rigaud D; Bouriel C; Delecroix V; Garin E; Rouquette S; Resche I; Kerbrat P; Chatal JF; Campone M
J Clin Oncol; 2006 Dec; 24(34):5366-72. PubMed ID: 17088570
[TBL] [Abstract][Full Text] [Related]
33. Early reduction in standardized uptake value after one cycle of neoadjuvant chemotherapy measured by sequential FDG PET/CT is an independent predictor of pathological response of primary breast cancer.
Ueda S; Tsuda H; Saeki T; Osaki A; Shigekawa T; Ishida J; Tamura K; Abe Y; Omata J; Moriya T; Fukatsu K; Yamamoto J
Breast J; 2010; 16(6):660-2. PubMed ID: 21070448
[No Abstract] [Full Text] [Related]
34. [18F]-3'Deoxy-3'-fluorothymidine positron emission tomography and breast cancer response to docetaxel.
Contractor KB; Kenny LM; Stebbing J; Rosso L; Ahmad R; Jacob J; Challapalli A; Turkheimer F; Al-Nahhas A; Sharma R; Coombes RC; Aboagye EO
Clin Cancer Res; 2011 Dec; 17(24):7664-72. PubMed ID: 22028493
[TBL] [Abstract][Full Text] [Related]
35. The role of PET and MRI in evaluating the feasibility of skin-sparing mastectomy following neoadjuvant therapy.
Malya FU; Kadioglu H; Bektasoglu HK; Gucin Z; Yildiz S; Guzel M; Erdogan EB; Yucel S; Ersoy YE
J Int Med Res; 2018 Feb; 46(2):626-636. PubMed ID: 29332418
[TBL] [Abstract][Full Text] [Related]
36. Brown adipose tissue activity in relation to weight gain during chemotherapy in breast cancer patients: a pilot study.
Gadea E; Thivat E; Merlin C; Paulon R; Kwiatkowski F; Chadeyras JB; Coudert B; Boirie Y; Morio B; Durando X
Nutr Cancer; 2014; 66(7):1092-6. PubMed ID: 25157743
[TBL] [Abstract][Full Text] [Related]
37. Positron emission tomography and neoadjuvant therapy of breast cancer.
Cochet A; Generali D; Fox SB; Ferrozzi F; Hicks RJ
J Natl Cancer Inst Monogr; 2011; 2011(43):111-5. PubMed ID: 22043055
[TBL] [Abstract][Full Text] [Related]
38. [Early prediction of response to primary chemotherapy by sequential FDG -PET in patients with advanced breast cancer].
Momiyama N; Ishikawa T; Ichikawa Y; Shimada H; Katayama A; Ozawa Y
Nihon Rinsho; 2007 Jun; 65 Suppl 6():385-8. PubMed ID: 17679210
[No Abstract] [Full Text] [Related]
39. A decrease in brown adipose tissue activity is associated with weight gain during chemotherapy in early breast cancer patients.
Ginzac A; Barres B; Chanchou M; Gadéa E; Molnar I; Merlin C; Coudert B; Thivat E; Durando X
BMC Cancer; 2020 Feb; 20(1):96. PubMed ID: 32019525
[TBL] [Abstract][Full Text] [Related]
40. Prediction of Primary Tumour and Axillary Lymph Node Response to Neoadjuvant Chemo(Targeted) Therapy with Dedicated Breast [18F]FDG PET/MRI in Breast Cancer.
de Mooij CM; van Nijnatten TJA; Goorts B; Kooreman LFS; Raymakers IWM; van Meijl SPL; de Boer M; Keymeulen KBMI; Wildberger JE; Mottaghy FM; Lobbes MBI; Smidt ML
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672354
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
